✦ LIBER ✦

Time course of the cytotoxicity of blood mononuclears in patients with bladder cancer during endolymphatic immunotherapy with lymphokine-activated killers and recombinant interleukin-2

✍ Scribed by N. V. Malakhova; K. M. Figurin; N. S. Fedorova; M. V. Kiselevskii; S. N. Bykovskaya

Publisher: Springer US
Year: 1996
Tongue: English
Weight: 303 KB
Volume: 121
Category: Article
ISSN: 0007-4888
DOI: 10.1007/bf02446629

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of suppressor and cytotoxic a

Comparison of suppressor and cytotoxic activity of blood mononuclears during adaptive immunotherapy of cancer patients with lymphokine-activated killer cells with a low dose of recombinant interleukin-2

✍ I. F. Abronina; T. A. Kupriyanova; A. V. Bolvachova; S. N. Bykovskaya; O. M. Dro 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 345 KB

Recombinant interleukin-2 and lymphokine

Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells

✍ Claudio Fortis; Elisabetta Ferrero; Carlo Besana; Mauro Biffi; Silvia Heltai; La 📂 Article 📅 1990 🏛 Springer-Verlag 🌐 English ⚖ 735 KB

Lack of correlation between peripheral b

Lack of correlation between peripheral blood lymphokine-activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2

✍ A. K. Ghosh; H. Dazzi; N. Thatcher; M. Moore 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 634 KB

A phase-1/11 study of recombinant interleukin 2 (rll-2) was performed in 31 melanoma patients. The first dose of rlL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum t